Onkologie. 2025:19(5):275-282 | DOI: 10.36290/xon.2025.050

Immunotherapy in the treatment of metastatic non-small cell lung cancer

Ondřej Bílek
Oddělení klinické onkologie, Masarykův onkologický ústav, Brno

Immune checkpoint inhibition has become an integral component of standard treatment algorithms across all lines of therapy. PD-1 and PD-L1 inhibitors are indicated as monotherapy, as part of dual checkpoint blockade with CTLA-4 inhibitors, or in combination with other therapeutic modalities such as chemotherapy, anti-angiogenic agents, and radiotherapy. The use of immunotherapy has significantly improved survival outcomes even in advanced disease stages and enables durable clinical responses in a subset of patients.

Keywords: NSCLC, immunotherapy, PD-1, PD-L1.

Accepted: November 25, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bílek O. Immunotherapy in the treatment of metastatic non-small cell lung cancer. Onkologie. 2025;19(5):275-282. doi: 10.36290/xon.2025.050.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 15.12.2026

    References

    1. nscl_blocks.pdf. Accessed January 30, 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf.
    2. Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018;36(9):850-858. doi:10.1200/JCO.2017.75.1644. Go to original source... Go to PubMed...
    3. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264-iv266. doi: 10.1093/annonc/mdy162. Go to original source... Go to PubMed...
    4. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Go to original source... Go to PubMed...
    5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 2019;14(10):S243. doi: 10.1016/j.jtho.2019.08.483. Go to original source...
    6. Mariamidze E, Mezquita L. ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update. ESMO Open. 2021;6(1). doi: 10.1016/j.esmoop.2020.100022. Go to original source... Go to PubMed...
    7. keytruda-epar-product-information_en.pdf. Accessed February 15, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.
    8. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Go to original source... Go to PubMed...
    9. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(14):1505-1517. doi:10.1200/JCO.19.03136. Go to original source... Go to PubMed...
    10. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Go to original source... Go to PubMed...
    11. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Go to original source... Go to PubMed...
    12. Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Go to original source... Go to PubMed...
    13. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2015;373(17):1627-1639. doi: 10.1056/NEJMoa1507643. Go to original source... Go to PubMed...
    14. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2015;373(2):123-135. doi: 10.1056/NEJMoa1504627. Go to original source... Go to PubMed...
    15. Borghaei H, Brahmer JR, Horn L, et al. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. JCO. 2016;34(15_suppl):9025-9025. doi: 10.1200/JCO.2016.34.15_suppl.9025. Go to original source...
    16. Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. JCO. Published online January 15, 2021:JCO.20.01605. doi: 10.1200/JCO.20.01605. Go to original source... Go to PubMed...
    17. opdivo-epar-product-information_en.pdf. Accessed February 15, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf.
    18. Reck M, Ciuleanu TE, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. JCO. 2020;38(15_suppl):9501-9501. doi: 10.1200/JCO.2020.38.15_suppl.9501. Go to original source...
    19. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. The Lancet Oncology. 2021;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Go to original source... Go to PubMed...
    20. Opdivo | European Medicines Agency. Accessed May 11, 2024. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo.
    21. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. Go to original source... Go to PubMed...
    22. Özgüroğlu M, Kilickap S, Sezer A, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Go to original source... Go to PubMed...
    23. Libtayo | European Medicines Agency. Accessed May 11, 2024. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo.
    24. Makharadze T, Gogishvili M, Melkadze T, et al. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023;18(6):755-768. doi:10.1016/j.jtho.2023.03.008. Go to original source... Go to PubMed...
    25. Baramidze A, Gogishvili M, Melkadze T, et al. 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. Immuno-Oncology and Technology. 2022;16:100234. doi: 10.1016/j.iotech.2022.100234. Go to original source...
    26. tecentriq-epar-product-information_en.pdf. Accessed February 21, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf.
    27. Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. Journal of Thoracic Oncology. 2021;16(1):140-150. doi:10.1016/j.jtho.2020.09.022. Go to original source... Go to PubMed...
    28. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. Go to original source... Go to PubMed...
    29. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine. 2018;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Go to original source... Go to PubMed...
    30. Socinski MA, Mok TS, Nishio M, et al. Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. Cancer Res. 2020;80(16 Supplement):CT216-CT216. doi:10.1158/1538-7445.AM2020-CT216. Go to original source...
    31. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. The Lancet Respiratory Medicine. 2019;7(5):387-401. doi:10.1016/S2213-2600(19)30084-0. Go to original source... Go to PubMed...
    32. Johnson ML, Cho BC, Luft A, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology. Published online November 3, 2022. doi: 10.1200/JCO.22.00975. Go to original source... Go to PubMed...
    33. EU Approves Durvalumab/Tremelimumab Combo for Advanced Lung, Liver Cancers. OncLive. February 22, 2023. Accessed May 11, 2024. Available from: https://www.onclive.com/view/eu-approves-durvalumab-tremelimumab-combo-for-advanced-lung-liver-cancers.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.